antibioticsАнтибиотики и ХимиотерапияAntibiot Khimioter = Antibiotics and Chemotherapy0235-2990ООО «Издательство ОКИ»antibiotics-258Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL PAPERSБиологическая стоимость устойчивости Helicobacter pylori к рифампицинуBiological Cost of Helicobacter pylori Rifampicin ResistanceМомыналиевК. Т.MomynalievK. T.noemail@neicon.ruЧелышеваВ. В.ChelyshevaV. V.noemail@neicon.ruАкопианТ. А.AkopianT. A.noemail@neicon.ruСелезневаО. В.SeleznevaO. V.noemail@neicon.ruГоворунВ. М.GovorunV. M.noemail@neicon.ruНаучно-исследовательский институт физико-химической медицины Федерального агентства по здравоохранению и социальному развитию РФ, МоскваРоссияResearch Institute of Physico-Chemical Medicine, MoscowRussian Federation200913052020549-101015Copyright © ООО «Издательство ОКИ», 20202020ООО «Издательство ОКИ»ООО «Издательство ОКИ»https://www.antibiotics-chemotherapy.ru/jour/about/submissions#copyrightNoticehttps://www.antibiotics-chemotherapy.ru/jour/article/view/258

Для определения биологической стоимости устойчивости H.pylori к рифампицину (РИФ) оценивали частоту возникновения мутантов рифампициноустойчивых (РИФР) клонов микроорганизма при адаптации к офлоксацину и метронидазолу. Было показано, что мутации в rpoB гене, обеспечивающие устойчивость H.pylori к РИФ, имеют биологическую стоимость, которые, однако, скомпенсированы дополнительными мутациями в геноме микроорганизма. Сравнение частоты возникновения мутантов в присутствии метронидазола показало, что в результате приобретённой устойчивости к РИФ меняются адаптационные возможности РИФр клонов H.pylori к метронидазолу. Так, для одного из РИФр клонов было показано существенное увеличение частоты мутирования (>700 раз), а также широкий спектр мутаций, обеспечивающих устойчивость к метронидазолу по сравнению с исходным штаммом H.pylori 26695. Описанные явления могут говорить, с одной стороны, о том, что адаптация к РИФ меняет свойства клетки таким образом, что повышает её способность мутировать, с другой — направленная селекция выявляет гипермутабельные клетки в бактериальной популяции, которые, по-видимому, всегда присутствуют в популяции.

The frequence of mutations in the rifampicin resistant (RIFr) clones of microorganisms after adaption to ofloxacin and metronidazole was investigated to estimate the biological cost of H.pylori rifampicin (RIF) resistance. Mutations in rpoB gene responsible for RIF resistance of H.pylori were shown to have biological cost and be compensated by additional mutations in the microorganism genome. Comparison of the mutation frequency in the presence of metroniazole demonstrated that the acquired resistance to RIF resulted in changing of the adaptative capacity of the RIFr clones of H.pylori to metronidazole. Thus, a significant increase of the mutation frequency (> 700 times) in one of the RIFr clones and a broad spectrum of the mutations responsible for resistance to metronidazole vs. the H.pylori initial strain 26695 were observed. The findings could be evident of the fact that the adaptation to RIF changed the properties of the cell on one hand in such a way that its mutation capacity increased and that the target selection on the other hand revealed hypermutable cells, likely usual for the bacterial population.

устойчивость к рифампицинунаправленная селекцияофлоксацинметронидазолHelicobacter pyloriHelicobacter pyloririfampicin resistancetarget selectionofloxacinmetronidazoleReferencesGuillemot D. Antibiotic use in humans and bacterial resistance. Curr Opin Microbiol 1999; 2: 494—498.Guillemot D. Antibiotic use in humans and bacterial resistance. Curr Opin Microbiol 1999; 2: 494—498.Wichelhaus T.A., Böddinghaus B., Besier S. et al. Biological cost of rifampin resistance from the perspective of Staphylococcus aureus. Antimicrob Agents Chemother 2002; 46: 3381—3385.Wichelhaus T.A., Böddinghaus B., Besier S. et al. Biological cost of rifampin resistance from the perspective of Staphylococcus aureus. Antimicrob Agents Chemother 2002; 46: 3381—3385.Austin D. J., Kristinsson K. G., Anderson R. M. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc Natl Acad Sci USA. 1999; 96: 1152—1156.Austin D. J., Kristinsson K. G., Anderson R. M. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc Natl Acad Sci USA. 1999; 96: 1152—1156.Seppala H., Klaukka T., Vuopio-Varkila J. et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. New Engl J Med 1997; 337: 441—446.Seppala H., Klaukka T., Vuopio-Varkila J. et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. New Engl J Med 1997; 337: 441—446.Hawkey P. M. Molecular epidemiology of clinically significant antibiotic resistance genes. Br J Pharmacol 2008; 153: 406—413.Hawkey P. M. Molecular epidemiology of clinically significant antibiotic resistance genes. Br J Pharmacol 2008; 153: 406—413.Stefani S., Agodi A. Molecular epidemiology of antibiotic resistance. Int J Antimicrob Agents 2000; 13: 143—153.Stefani S., Agodi A. Molecular epidemiology of antibiotic resistance. Int J Antimicrob Agents 2000; 13: 143—153.O'Sullivan D. M., McHugh T. D., Gillespie S. H. Analysis of rpoB and pncA mutations in the published literature: an insight into the role of oxidative stress in Mycobacterium tuberculosis evolution? J Antimicrob Chemother 2005. 55: 674—679.O'Sullivan D. M., McHugh T. D., Gillespie S. H. Analysis of rpoB and pncA mutations in the published literature: an insight into the role of oxidative stress in Mycobacterium tuberculosis evolution? J Antimicrob Chemother 2005. 55: 674—679.O'Neill A. J., Huovinen T., Fishwick C. W., Chopra I. Molecular genetic and structural modelling studies of Staphylococcus aureus RNA polymerase and the fitness of rifampin resistance genotypes in relation to clinical prevalence. Antimicrob Agents Chemother 2006; 50: 298—309.O'Neill A. J., Huovinen T., Fishwick C. W., Chopra I. Molecular genetic and structural modelling studies of Staphylococcus aureus RNA polymerase and the fitness of rifampin resistance genotypes in relation to clinical prevalence. Antimicrob Agents Chemother 2006; 50: 298—309.Pfister P., Corti N., Hobbie S. et al. 23S rRNA base pair 2057-2611 determines ketolide susceptibility and fitness cost of the macrolide resistance mutation 2058A — G. Proc Natl Acad Sci USA 2005; 102: 5180—5185.Pfister P., Corti N., Hobbie S. et al. 23S rRNA base pair 2057-2611 determines ketolide susceptibility and fitness cost of the macrolide resistance mutation 2058A — G. Proc Natl Acad Sci USA 2005; 102: 5180—5185.Wolter N., Smith A. M., Farrell D. J. et al. Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus. Antimicrob Agents Chemother 2005; 49: 3554—3557.Wolter N., Smith A. M., Farrell D. J. et al. Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus. Antimicrob Agents Chemother 2005; 49: 3554—3557.Nilsson A. I., Zorzet A., Kanth A. et al. Reducing the fitness cost of antibiotic resistance by amplification of initiator tRNA genes. Proc Natl Acad Sci USA 2006; 103: 6976—6981.Nilsson A. I., Zorzet A., Kanth A. et al. Reducing the fitness cost of antibiotic resistance by amplification of initiator tRNA genes. Proc Natl Acad Sci USA 2006; 103: 6976—6981.Heep M., Beck D., Bayerdorffer E., Lehn N. Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother 1999; 43: 1497—1499.Heep M., Beck D., Bayerdorffer E., Lehn N. Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother 1999; 43: 1497—1499.Moore R. A., Beckthold B., Wong S. et al. Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin resistant mutants of Helicobacter pylori. Antimicrob. Agents Chemother. 1995. 39: 107—111.Moore R. A., Beckthold B., Wong S. et al. Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin resistant mutants of Helicobacter pylori. Antimicrob. Agents Chemother. 1995. 39: 107—111.Goodwin A., Kersulyte D., Sisson G. et al. Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen insensitive NADPH nitroreductase. Mol Microbiol 1998; 28: 383—393.Goodwin A., Kersulyte D., Sisson G. et al. Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen insensitive NADPH nitroreductase. Mol Microbiol 1998; 28: 383—393.Sisson G., Jeong J.Y. , Goodwin A. et al. Metronidazole activation is mutagenic and causes DNA fragmentation in Helicobacter pylori and in Escherichia coli containing a cloned H.pylori rdxA (nitroreductase) gene. J Bacteriol 2000; 182: 5091—5096.Sisson G., Jeong J.Y. , Goodwin A. et al. Metronidazole activation is mutagenic and causes DNA fragmentation in Helicobacter pylori and in Escherichia coli containing a cloned H.pylori rdxA (nitroreductase) gene. J Bacteriol 2000; 182: 5091—5096.Ge Z., Taylor D. E. Rapid polymerase chain reaction screening of Helicobacter pylori chromosomal point mutations. Helicobacter 1997; 2: 127—131.Ge Z., Taylor D. E. Rapid polymerase chain reaction screening of Helicobacter pylori chromosomal point mutations. Helicobacter 1997; 2: 127—131.Ge Wang, Trevor J. M. Wilson, Qin Jiang, Diane E. Taylor. Spontaneous mutations that confer antibiotic resistance in Helicobacter pylori. Antimicrob Agents Chemother 2001; 45: 727—733.Ge Wang, Trevor J. M. Wilson, Qin Jiang, Diane E. Taylor. Spontaneous mutations that confer antibiotic resistance in Helicobacter pylori. Antimicrob Agents Chemother 2001; 45: 727—733.Campbell E. A., Korzheva N., Mustaev A. et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 2001; 104: 901—912.Campbell E. A., Korzheva N., Mustaev A. et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 2001; 104: 901—912.Jeong J. Y., Mukhopadhyay A. K., Akada J. K. et al. Roles of FrxA and RdxA nitroreductases of Helicobacter pylori in susceptibility and resistance to metronidazole. J Bacteriol 2001; 183: 5155—5162.Jeong J. Y., Mukhopadhyay A. K., Akada J. K. et al. Roles of FrxA and RdxA nitroreductases of Helicobacter pylori in susceptibility and resistance to metronidazole. J Bacteriol 2001; 183: 5155—5162.Jeong J. Y., Mukhopadhyay A.K., Dailidiene D. et al. Sequential inactivation of rdxA (HP0954) and frxA (HP0642) nitroreductase genes cause moderate and high-level metronidazole resistance in Helicobacter pylori. J Bacteriol 2000; 182: 5082—5090.Jeong J. Y., Mukhopadhyay A.K., Dailidiene D. et al. Sequential inactivation of rdxA (HP0954) and frxA (HP0642) nitroreductase genes cause moderate and high-level metronidazole resistance in Helicobacter pylori. J Bacteriol 2000; 182: 5082—5090.Albert T. J., Dailidiene D., Dailide G. et al. Mutation discovery in bacterial genomes: metronidazole resistance in Helicobacter pylori. Nature Methods 2005; 2: 951—953.Albert T. J., Dailidiene D., Dailide G. et al. Mutation discovery in bacterial genomes: metronidazole resistance in Helicobacter pylori. Nature Methods 2005; 2: 951—953.

The authors declare that there are no conflicts of interest present.